Opinion

Video

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Author(s):

Sub Subramony, M.D.

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the pathophysiology and incidence rate of the condition.

Video content above is prompted by the following:

  • Describe the typical clinical presentation of FA in terms of age of onset, initial symptoms, and life expectancy?
  • Can you summarize the pathophysiology and incidence rate of Friedreich's Ataxia (FA)? 
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Past studies have explored the association between motor and cardiac function in younger patients with DMD, but there is a lack of research on this relationship as patients with DMD age. | Image credit: Nana_studio - stock.adobe.com
January 13th 2025

Later Loss of Ambulation Linked With Better Heart Health in DMD

Rose McNulty
The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD).
Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
January 6th 2025

Pain May Be Indicator of MS Prior to Disease Onset: Study

AJMC Contributor
Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.
Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com
January 3rd 2025

Meta-Analysis: Vascular Function Worse in People With MS

Jared Kaltwasser
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
lab test tubes | Image credit: kwanchaift – stock.adobe.com
December 22nd 2024

Study Highlights Trends, Emerging Innovations in DMD Research

Hayden E. Klein
An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.
Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com
October 9th 2024

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

Hayden E. Klein
A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).
Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com
September 26th 2024

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

Rose McNulty
In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo